Navigation Links
Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Date:10/30/2008

LONDON and NEW YORK, Oct. 30 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on first-in-class novel, non-steroidal anti-inflammatory drugs, announced today that Dr. Yuval Cohen, President of Morria, will deliver a presentation at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, Nov. 10 from 10:45 to 11:10 a.m. in the Louis room (4th Floor) at The New York Palace Hotel.

Dr. Cohen's presentation will provide an overview of Morria's development of its leading clinical programs in allergic rhinitis (hay fever) and skin inflammation (contact dermatitis), as well as its pre-clinical progress in asthma, inflammatory bowel disease, ophthalmology and cystic fibrosis. The presentation will include a review of the clinical results reported from Morria's recently completed Phase II double blind placebo controlled study in 105 patients suffering from allergic rhinitis, a study that also included a steroid comparator.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focusing on the development of novel, anti-inflammatory pharmaceuticals termed Multi-Functional Anti-Inflammatory Drugs (MFAID). Morria is determined to become a pivotal player in the anti-inflammatory drug market through the introduction of novel drugs for the treatment of a variety of acute and chronic inflammatory conditions including respiratory, skin, airway and gastro-intestinal inflammatory diseases. For more information please visit http://www.morria.com.

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - Persons in the business of disseminating information.

Richard Lewis Communications, Inc.

212-827-0020

Cecelia Heer - Investors

cheer@rlcinc.com

Tim Rathschmidt - Media

trathschmidt@rlcinc.com


'/>"/>
SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
2. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
3. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
4. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
5. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
6. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
7. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
9. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
10. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
11. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... May 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great Point Partners ... to grow. CSM has doubled in size over the past six months with ... strategy. , Roger Gasper joins CSM as Chief Financial Officer. Roger has over ...
(Date:5/18/2017)... SANTA BARBARA, CALIFORNIA (PRWEB) , ... May 17, ... ... risk management, technological innovation and business process optimization firm for the life sciences ... the Chairman of the UDIs and Traceability for Medical Devices conference in Brussels, ...
(Date:5/18/2017)... ... May 18, 2017 , ... When James Sherley, was notified earlier this year that ... Brands for the Year 2017 by The Silicon Review , he was not surprised ... progress increasing Asymmetrex’s value, but this recognition by Silicon Valley was particularly meaningful. Our ...
(Date:5/16/2017)... , ... May 16, 2017 , ... ... and cancer diagnostics, has released its ClearID Lung Cancer blood test. Leveraging a ... cancer, this new test is designed to quickly and accurately identify tumor-related genetic ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):